StockData
Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc. (RCKT) company profile

RCKTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 3/30
$2.11+0.00 (0.00%)

Close on Nov 18, 2026Market cap $231.62MP/E –Yield –

About Rocket Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company that focuses on developing gene therapies for rare and life-threatening diseases. The company develops treatments using adeno-associated virus and lentiviral vector platforms to target conditions such as Danon disease, Fanconi anemia, pyruvate kinase deficiency, leukocyte adhesion deficiency-I, and cardiomyopathies. Its primary customers and end users include patients afflicted with severe genetic disorders, alongside the physicians, healthcare providers, and clinical institutions that treat these conditions.

The company conducts research, preclinical and clinical testing, and direct manufacturing operations in the United States, while pursuing clinical and commercial relationships abroad, particularly across the European Union. Its operational footprint includes leased office space in New York City as well as facilities in New Jersey. Rocket Pharmaceuticals maintains its principal executive offices and headquarters in Cranbury, New Jersey.

Summary of the business section of Rocket Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Rocket Pharmaceuticals, Inc.
Headquarters
New York, NY
Address
350 Fifth Avenue, Suite 7530 10118
Phone
(646) 440-9100
Employees
202, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
EISNERAMPER LLP, Iselin, New Jersey

Stock & identifiers

Ticker
RCKT
Former tickers
ITEK until Mar 7, 2018
Exchange
Nasdaq
IPO date
Feb 19, 2015
Shares outstanding
110M, Jul 31, 2026
Public float
$212.50M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-4 reverse, Jan 5, 2018
SEC CIK
1281895
CUSIP
77313F106
ISIN
US77313F1066
FIGI
BBG000WG3567
Share class FIGI
BBG001T92156
LEI
549300R7VV82YUIN4Y93
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Martin WilsonGeneral Counsel541,013
Gaurav ShahCEO1,459,812
Sarbani ChaudhuriSee Remarks257,937
Christopher James StevensChief Operating Officer505,784
Joseph ManhedePrincipal Accounting Officer52,576
John MilitelloSee Remarks89,780
Syed Ali-aamir RizviChief Medical Officer407,874
Jonathan David SchwartzSee Remarks299,064
Aaron OndreyChief Financial Officer128,173
Kinnari PatelSee Remarks573,628
David P. SouthwellDirector317,646
Roderick WongDirector18,263,956
Fady Ibraham MalikDirector52,862
Mikael DolstenDirector67,082
Peter FongDirector76,195
Carsten BoessDirector52,862
Elisabeth BjorkDirector50,000
Rtw Investments, LpDirector18,295,124
Gotham MakkerDirector1,017,412
Pedro P. GranadilloDirector54,734
Piratip PratumsuwanDirector30,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$3.51M-$327.60K$3.48M$18$0
FY2024$6.84M-$1.67M$3.07M$64$114
FY2023$8.01M$12.37M$3.48M$153$115
FY2022$6.55M$5.19M$2.71M$86$111
FY2021$7.92M-$4.33M$3.60M$96$125
FY2020$6.86M$21.73M$1.90M$241$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Gaurav D. Shah, M.D.
Chief Executive Officer
$671.08K–$806.75K$1.61M$403.05K$15.99K$3.51M-49%
Christopher Stevens
Chief Operating Officer
$242.31K$125.00K$1.25M$1.70M$236.25K$911$3.56M–
Martin Wilson
General Counsel and Chief Corporate Officer, Senior Vice President, Interim Principal Financial Officer
$488.28K–$1.74M$892.68K$265.87K$13.32K$3.40M+61%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 19, 2015
Offer price
$6.00
Securities offered
6,667,000
Gross proceeds
$40.00M
Exchange
Nasdaq
First trading day
Feb 18, 2015
First-day close
$6.000.0%
Lock-up ends (est.)
Aug 17, 2015

“Our common stock has been approved for listing on The NASDAQ Global Market under the symbol “ITEK.” The initial public offering price of our common stock is $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 202 full-time employees, of whom 195 were located in the U.S., 6 in Spain, and 1 in Italy.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?